DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Theolair (Theophylline) - Summary

 
 



THEOLAIR SUMMARY

Theolair™
(theophylline tablets USP)
TABLETS

Theophylline is structurally classified as a methylxanthine. It occurs as a white, odorless, crystalline powder with a bitter taste.

Theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.


See all Theolair indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Theolair (Theophylline)

New Cause Eyed for Adult-Onset Asthma
Source: Medscape Headlines [2015.02.20]
The cause of adult-onset asthma remains elusive, but a new study looks at the role that micronutrients may play.
Medscape Pulmonary Medicine

Epigenetic study highlights drug targets for allergies and asthma
Source: Allergy News From Medical News Today [2015.02.20]
Scientists have discovered over 30 new genes that predispose people to allergies and asthma, some of which could be targets for new drugs.

New genes discovered associated with asthma and allergies
Source: Allergy News From Medical News Today [2015.02.20]
Researchers have identified over 30 new genes that give people a predisposition towards asthma and allergies. These genes may provide new targets for these conditions.

CU School Of Medicine researchers offer new target for treating asthma
Source: Respiratory / Asthma News From Medical News Today [2015.02.20]
Researchers have found a potential new target for treating asthma, according to a study led by researchers at the University of Colorado School of Medicine at the Anschutz Medical Campus and...

Gut Microflora in Cutting-Edge Allergy and Asthma Care
Source: Medscape Allergy & Clinical Immunology Headlines [2015.02.17]
This year's American Academy of Allergy, Asthma & Immunology conference will explore the role of the microbiome. Other hot topics will include immunotherapy, Ebola, and biomarkers.
Medscape Medical News

more news >>

Published Studies Related to Theolair (Theophylline)

Beneficial effects of theophylline infusions in surgical patients with intra-abdominal hypertension. [2011.08]
BACKGROUND: Intra-abdominal hypertension (IAH) can cause high mortality. Recently, we found that IAH was associated with increased serum levels of adenosine and interleukin 10. Our present "hypothesis-generated study" was based on the above mentioned results... CONCLUSIONS: Adenosine receptor antagonism with T following IAH diagnosis resulted in markedly reduced mortality in patients with moderated IAH (<20 mmHg). Theophylline-associated mortality reduction may be related to improved renal perfusion and improved MAP, presumably caused by adenosine receptor blockade. Because this study was not a randomized controlled study, these compelling observations require further multicentric clinical confirmation.

Study investigating pharmacokinetic interaction between theophylline and roflumilast in healthy adults. [2011.07]
OBJECTIVE: To investigate whether a pharmacokinetic drug-drug interaction exists between theophylline (THEO), a CYP1A2 substrate with a narrow therapeutic index, and the concomitant substrate roflumilast (ROF), a novel selective PDE4 inhibitor partially metabolized by CYP1A2... CONCLUSIONS: Neither ROF nor its main metabolite had any impact on the metabolism of the concomitant CYP1A2 substrate THEO in humans. Though co-administration of THEO resulted in a minor increase (28%) in total ROF exposure, no safety or tolerability concerns and no altered total PDE4 inhibition of both ROF and R-NO, were observed.

Prevention of contrast-induced acute kidney injury by theophylline in elderly patients with chronic kidney disease. [2010.11]
Although the optimal strategy for preventing contrast-induced acute kidney injury (CI-AKI) has not yet been established, the current strategy focuses on adequate periprocedural hydration, the use of a low amount of low or iso-osmolar contrast medium, and the application of adjunctive therapies, including hemofiltration, hemodialysis and drugs...

Prevention of contrast-induced acute kidney injury by theophylline in elderly patients with chronic kidney disease. [2010.09.29]
Although the optimal strategy for preventing contrast-induced acute kidney injury (CI-AKI) has not yet been established, the current strategy focuses on adequate periprocedural hydration, the use of a low amount of low or iso-osmolar contrast medium, and the application of adjunctive therapies, including hemofiltration, hemodialysis and drugs...

Adenosine receptor inhibition with theophylline attenuates the skin blood flow response to local heating in humans. [2010.09]
Mechanisms underlying the robust cutaneous vasodilatation in response to local heating of human skin remain unresolved. Adenosine receptor activation has been shown to induce vasodilatation via nitric oxide, and a substantial portion of the plateau phase to local heating of human skin has been shown to be dependent on nitric oxide...

more studies >>

Clinical Trials Related to Theolair (Theophylline)

Rosiglitazone Versus Theophylline in Asthmatic Smokers [Completed]
Asthmatic smokers display a blunted response to both inhaled and oral corticosteroid treatments and are at increased risk for exacerbations and near fatal asthma. The prevalence of smoking in asthmatics runs between 20-30%. Therefore, new, more efficacious treatments are required.

Recent work has demonstrated a mechanism which may explain steroid resistance. A commonly used drug called theophylline can reverse this steroid resistance in laboratory studies. Another commonly used drug, rosiglitazone can reverse smoking induced lung inflammation in laboratory studies.

The investigators aim to study the effects of these drugs on smoking asthmatics' lung function and other parameters including quality of life and asthma control.

Effects of Low-Dose Theophylline During Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [Completed]
Molecular mechanisms of COPD exacerbations and the modulating effect of low dose theophylline on that inflammation are elucidated in this project. NF-kappa B-dependent pathway and acetylation status of nuclear histones are to be studied. Design: controlled, prospective and randomized study with or without theophylline, a potent HDAC activator. Objectives: 1) To determine NF-kB activation, histone deacetylase (HDAC) and histone acetyl-transferase (HAT) activity in sputum macrophages and blood monocytes during an episode of exacerbation and 3 months later, once stability is achieved. To correlate these measurements with inflammatory and oxidative stress markers and with pulmonary function and clinical variables. 2) To assess the effect of theophylline on previous molecular, functional and clinical data. Method: 25 patients with COPD will be recruited during an episode of exacerbation requiring hospitalization. NF-kB activation, HDAC and HAT activity, markers of inflammation and oxidative stress will be determined with specific assays. These determinations will be repeated once the patient is stable and compared with smokers and non smoker controls with normal lung function

Theophylline in Chronic Obstructive Pulmonary Disease [Recruiting]
This will be a prospective randomized double-blinded parallel group clinical trial evaluating the short-term effects of theophylline therapy on exercise duration and lung function in patients with chronic obstructive pulmonary disease already receiving both tiotropium and a long-acting beta-agonist (salmeterol or formoterol).

Theophylline in Treating Cancer Patients With Shortness of Breath [Active, not recruiting]
RATIONALE: Theophylline may help to relieve shortness of breath in patients who have cancer. It is not yet known whether theophylline is more effective than no further treatment for shortness of breath.

PURPOSE: Randomized phase III trial to determine the effectiveness of theophylline in treating shortness of breath in patients who have cancer.

Acetylcysteine, Theophylline, and a Combination of Both in the Prophylaxis of Contrast-Induced Nephropathy [Completed]
Several studies demonstrated a significant reduction of contrast-induced nephropathy (CIN; definition: increase in serum creatinine of >=0. 5mg/dl and/or >=25% increase within 48h after contrast-medium) by acetylcysteine (A) or theophylline (T). However, the results are contradictory. Therefore, it was the aim of our double-blind study to compare the effects of A, T, a combination of A and T (A+T), and placebo (P).

more trials >>


Page last updated: 2015-02-20

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015